Pave Preps First-of-its-Kind Lung Biopsy Device

Posted: Updated:
Pave says its full core biopsy device gives clinicians a smaller needle than ever before to collect lung biopsies. Pave says its full core biopsy device gives clinicians a smaller needle than ever before to collect lung biopsies.

Lung cancer is the leading cause of cancer death, and doctors are clamoring for a better way to diagnose it. A Zionsville-based startup is creating a lung biopsy device that it says gives clinicians something they’ve never had before: a smaller needle and a safer tissue-collection process that produces a clearer diagnosis for the patient. Pave LLC leaders say it meets a critical need as personalized medicine transforms cancer treatment, because the advances demand a better biopsy.

“If you’re a patient, one of the things you really don’t want to hear is, ‘You went through this biopsy, you went through all this pain, and the tissue we received from this biopsy was non-diagnostic,’” says Pave President Doug Knoll. “In other words, you’re going to have to do this biopsy again.”

Pave believes it can reduce this scenario by giving doctors a better biopsy tool that collects more tissue in a single procedure. A lung biopsy involves removing samples of lung tissue with a special needle to determine if cancer or lung disease are present. Pave Chief Executive Officer Debb Beck says lung biopsies are especially difficult, because they carry unique challenges.

“Anytime you’re poking a hole in the lung, you have increased risk to the patient,” says Beck.

“Pneumothorax (collapsed lung) can occur, when air gets in between the lung and chest wall,” says Knoll. “It’s a very serious condition that can be dangerous, painful and may require medical intervention. The smaller the needle, the less risk of something like that happening.”

And that’s why Pave is aiming to give clinicians a smaller needle than ever before to collect lung biopsies: 20 gauge. But the full core biopsy device has another critical feature that Pave says differentiates it from conventional ones: a cone.

“Envision a tube…the furthest part of the tube has a very thin, sharp edge, and the cone extends into the interior of the tube until it hits the inner diameter,” says Knoll. “When that’s fired forward into tissue, the tissue is then compressed into the cannula (thin tube) and retained when removing the device.”

Pave says the innovative cone design enables the device to collect a larger amount of tissue, which opens the door to pinpointing personalized cancer treatments based on the genetics of the individual’s disease. A 2015 personalized cancer medicine trial led by the National Cancer Institute revealed that one in five samples—obtained using standard biopsy methods—didn’t have enough cancerous cells to analyze, and therefore, the patients couldn’t be matched with personalized treatments.

Pave leaders believe the device solves a major market need for lung biopsies: the collection of a large sample in a smaller-than-ever package size.

“The more tissue that you can get from a patient, the more biomarkers that are available within it; you’re able to do more testing on it and target your treatment plan accordingly,” says Knoll. “So, the ideal would be to have a needle that has the maximum amount of tissue collection capability for its size.”

Beck says Pave has also simplified the design of the full core biopsy device, describing it as lightweight and balanced. These factors are important during a CT scan when the doctor needs to walk away and leave the device in place to check the placement before firing. 

Pave got its start in 2015 as a spinoff from Promex Technologies, where three of the startup’s five founders held leadership positions; Texas-based Argon Medical Devices acquired Promex. Pave is currently testing prototypes, refining the device and working with Indianapolis-based venture development organization Elevate Ventures to prepare for fundraising.

“Making a device for full core biopsy is technically challenging to begin with,” says Beck, “and to make it in an even smaller size is even more challenging.”

 “We have a solution that allows the device to be simple to manufacture, cheap to manufacture and allows it to be extremely effective for the job; that’s our biggest strength,” says Knoll. “We’re pushing hard, because this is a wide-open opportunity.”          

Knoll says Pave’s device collects the larger samples pathologists need, while maintaining a small profile.
Beck says the device has characteristics that make it ideal for lung biopsies and other respiratory diseases that require biopsy.
  • Perspectives

    • Chris Watts is president of the Indiana Fiscal Policy Institute.

      Revenue Forecast Shapes State Spending – And Surplus - Negotiations

      This week, the State Budget Committee heard an updated revenue forecast that could best be described as overcast but not stormy – yet.  Sales taxes, the largest source of state revenue, fared well from the December forecast – down a modest $15 million over the 2020-21 budget (and likely to be buoyed by new policies for online hotel and retail sales taxes moving through the legislature).  Individual income taxes showed a more dramatic decline, continuing a...

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Eli Lilly and Co. made the America’s Best Employers List

      Hoosier Companies Among 'America’s Best Employers'

      Forbes has released its list of America’s Best Employers for 2019. The Hoosier state was represented on the list by 12 companies, including Eli Lilly and Co., Cook Medical and NiSource among others.

    • The Vogue opened as a movie house in 1938, then reopened as a nightclub in 1977. (Picture Courtesy: The Vogue)

      Tech Vets Purchase Popular Indy Nightclub

      A group of Indianapolis tech entrepreneurs has bought a popular nightclub in the city's Broad Ripple neighborhood. High Alpha co-founder Eric Tobias and former MOBI executives Scott Kraege and Andrew Davis say they will retain the Vogue's current staff to manage the venue's day-to-day operations. The new owners say they will detail plans to reinvigorate the Vogue through enhanced fan experience and engagement in the coming months. Tobias, Kraege and Davis purchased the Vogue...

    • (rendering courtesy of the city of Fishers)

      Fishers Test Kitchen Looking For Applicants

      The city of Fishers has begun searching for chefs to take part in the first cohort at the Fishers Test Kitchen restaurant accelerator. Three participants will be selected for the accelerator, which aims to provide a space for them to grow, try new concepts and ultimately open their own restaurants. The accelerator, which the city says will be the first of its kind in the state, will open this fall inside the Sun King Brewing location in The Yard at Fishers District.

    • $9 Million Microscope to be Installed at Purdue

      Purdue University, the Indiana University School of Medicine, IU Bloomington, the University of Illinois at Urbana-Champaign, Eli Lilly and Co. and the Indiana Biosciences Research Institute have collaborated to bring the latest version of a cryo-electron microscope to Indiana. The nearly $9 million machine will be housed in Purdue's Discovery Park. 

    • Picture Courtesy: Becknell Industrial

      Becknell Industrial Planning $20M Project

      Carmel-based real estate firm Becknell Industrial is planning to invest nearly $20 million in a speculative facility in Merrillville. Our partners at The Times of Northwest Indiana report the move comes after the company found a tenant for another property it has in the Lake County city. The publication reports Becknell has an industrial building to the north of the new proposed site. That property is now being leased by Schilli Distribution. Becknell received a 10-year...